NCT07060365 2026-04-03
A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer
AstraZeneca
Phase 1/2 Withdrawn
AstraZeneca
Timser SAPI de CV
Karolinska Institutet
City of Hope Medical Center
University of Oklahoma
Baylor Research Institute